Home
EXEL
EXEL News

Latest Exelixis Inc. (EXEL) News on December 18, 2024

MT Newswires

a day ago

Exelixis Risk/Reward Now 'More Balanced' With 2025 Catalysts Priced In, BofA Says

MT Newswires

a day ago

BofA Securities Downgrades Exelixis to Neutral, $39 Price Target

SpringWorks Therapeutics (SWTX) Up 14.5% Since Last Earnings Report: Can It Continue?

Zacks

6 days ago

SpringWorks Therapeutics (SWTX) Up 14.5% Since Last Earnings Report: Can It Continue?

Why This 1 Value Stock Could Be a Great Addition to Your Portfolio

Zacks

7 days ago

Why This 1 Value Stock Could Be a Great Addition to Your Portfolio

Argus Research

8 days ago

EXEL: Rating decreased to a HOLD

Exelixis (EXEL) is an Incredible Growth Stock: 3 Reasons Why

Zacks

9 days ago

Exelixis (EXEL) is an Incredible Growth Stock: 3 Reasons Why

EXEL or INCY: Which Is the Better Value Stock Right Now?

Zacks

9 days ago

EXEL or INCY: Which Is the Better Value Stock Right Now?

AZN's Bladder Cancer sBLA for Imfinzi Gets FDA's Priority Tag

Zacks

9 days ago

AZN's Bladder Cancer sBLA for Imfinzi Gets FDA's Priority Tag

2 Biotech Stocks to Buy Hand Over Fist in December

Motley Fool

11 days ago

2 Biotech Stocks to Buy Hand Over Fist in December

Acadia (ACAD) Down 2.9% Since Last Earnings Report: Can It Rebound?

Zacks

12 days ago

Acadia (ACAD) Down 2.9% Since Last Earnings Report: Can It Rebound?

Why Is Editas (EDIT) Down 36.5% Since Last Earnings Report?

Zacks

14 days ago

Why Is Editas (EDIT) Down 36.5% Since Last Earnings Report?

Exelixis' (NASDAQ:EXEL) earnings growth rate lags the 29% CAGR delivered to shareholders

Simply Wall St.

14 days ago

Exelixis' (NASDAQ:EXEL) earnings growth rate lags the 29% CAGR delivered to shareholders

Argus Research

15 days ago

EXEL: Lowering target price to $39.00

Argus Research

15 days ago

Daily – Vickers Top Buyers & Sellers for 12/03/2024

MT Newswires

15 days ago

Exelixis Insider Sold Shares Worth $2,200,200, According to a Recent SEC Filing

Techne (TECH) Up 2.2% Since Last Earnings Report: Can It Continue?

Zacks

19 days ago

Techne (TECH) Up 2.2% Since Last Earnings Report: Can It Continue?

Here's Why Exelixis (EXEL) is a Strong Momentum Stock

Zacks

19 days ago

Here's Why Exelixis (EXEL) is a Strong Momentum Stock

Exelixis (EXEL) Up 10.8% Since Last Earnings Report: Can It Continue?

Zacks

20 days ago

Exelixis (EXEL) Up 10.8% Since Last Earnings Report: Can It Continue?

Exelixis to Webcast Fireside Chats as Part of Investor Conferences in December

Business Wire

21 days ago

Exelixis to Webcast Fireside Chats as Part of Investor Conferences in December

ODAC to Discuss Exelixis' Application for Cabometyx Label Expansion

Zacks

21 days ago

ODAC to Discuss Exelixis' Application for Cabometyx Label Expansion

Zacks Investment Ideas feature highlights: InterDigital, Futu and Exelixis

Zacks

21 days ago

Zacks Investment Ideas feature highlights: InterDigital, Futu and Exelixis

Argus Research

22 days ago

EXEL: Raising target price to $40.00

MT Newswires

22 days ago

Exelixis Says US FDA Will Review Supplemental NDA for Prospective Treatment for Pancreatic Tumors in March

Exelixis Provides Regulatory Update Related to Supplemental New Drug Application for Cabozantinib (CABOMETYX®) for the Treatment of Patients with Previously Treated Advanced Neuroendocrine Tumors

Business Wire

22 days ago

Exelixis Provides Regulatory Update Related to Supplemental New Drug Application for Cabozantinib (CABOMETYX®) for the Treatment of Patients with Previously Treated Advanced Neuroendocrine Tumors

End of Year Rally: 3 Stocks to Watch (IDCC, FUTU, EXEL)

Zacks

22 days ago

End of Year Rally: 3 Stocks to Watch (IDCC, FUTU, EXEL)

Exelixis Stock Surges 25% in a Month: Time to Buy or Sell?

Zacks

23 days ago

Exelixis Stock Surges 25% in a Month: Time to Buy or Sell?

Exelixis (EXEL) is a Top-Ranked Value Stock: Should You Buy?

Zacks

23 days ago

Exelixis (EXEL) is a Top-Ranked Value Stock: Should You Buy?

3 Reasons Growth Investors Will Love Exelixis (EXEL)

Zacks

a month ago

3 Reasons Growth Investors Will Love Exelixis (EXEL)

EXEL vs. CSLLY: Which Stock Is the Better Value Option?

Zacks

a month ago

EXEL vs. CSLLY: Which Stock Is the Better Value Option?

Zacks.com featured highlights Amazon, Maplebear, Exelixis and Doximity

Zacks

a month ago

Zacks.com featured highlights Amazon, Maplebear, Exelixis and Doximity

MT Newswires

a month ago

Exelixis Insider Sold Shares Worth $1,428,822, According to a Recent SEC Filing

Argus Research

a month ago

EXEL: Rating increased to a BUY

ADMA Biologics Inc (ADMA) Hits Fresh High: Is There Still Room to Run?

Zacks

a month ago

ADMA Biologics Inc (ADMA) Hits Fresh High: Is There Still Room to Run?

Vericel Stock Sees RS Rating Shoot Higher

Investor's Business Daily

a month ago

Vericel Stock Sees RS Rating Shoot Higher

What Makes Exelixis (EXEL) a Strong Momentum Stock: Buy Now?

Zacks

a month ago

What Makes Exelixis (EXEL) a Strong Momentum Stock: Buy Now?

Here's Why Exelixis (EXEL) is a Strong Momentum Stock

Zacks

a month ago

Here's Why Exelixis (EXEL) is a Strong Momentum Stock

MT Newswires

a month ago

Exelixis Insider Sold Shares Worth $3,394,510, According to a Recent SEC Filing

Exelixis to Webcast Fireside Chats as Part of Investor Conferences in November

Business Wire

a month ago

Exelixis to Webcast Fireside Chats as Part of Investor Conferences in November

Here's Why Exelixis (EXEL) is a Strong Value Stock

Zacks

a month ago

Here's Why Exelixis (EXEL) is a Strong Value Stock

Argus Research

a month ago

EXEL: Rating decreased to a HOLD

Here is Why Growth Investors Should Buy Exelixis (EXEL) Now

Zacks

a month ago

Here is Why Growth Investors Should Buy Exelixis (EXEL) Now

Earnings Estimates Rising for Exelixis (EXEL): Will It Gain?

Zacks

a month ago

Earnings Estimates Rising for Exelixis (EXEL): Will It Gain?

EXEL vs. CSLLY: Which Stock Should Value Investors Buy Now?

Zacks

a month ago

EXEL vs. CSLLY: Which Stock Should Value Investors Buy Now?

Exelixis (EXEL) Reliance on International Sales: What Investors Need to Know

Zacks

a month ago

Exelixis (EXEL) Reliance on International Sales: What Investors Need to Know

3 Magnificent Stocks Under $100 to Buy in November

Motley Fool

a month ago

3 Magnificent Stocks Under $100 to Buy in November

Exelixis, Inc. Just Recorded A 18% EPS Beat: Here's What Analysts Are Forecasting Next

Simply Wall St.

2 months ago

Exelixis, Inc. Just Recorded A 18% EPS Beat: Here's What Analysts Are Forecasting Next

Morningstar Research

2 months ago

Analyst Report: Exelixis, Inc.

Exelixis price target raised to $36 from $33 at Piper Sandler

TipRanks

2 months ago

Exelixis price target raised to $36 from $33 at Piper Sandler

Morningstar Research

2 months ago

Analyst Report: Exelixis, Inc.

Thomson Reuters StreetEvents

2 months ago

Q3 2024 Exelixis Inc Earnings Call

Exelixis Beats on Q3 Earnings and Sales, Raises Annual Outlook

Zacks

2 months ago

Exelixis Beats on Q3 Earnings and Sales, Raises Annual Outlook

Exelixis Inc (EXEL) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ...

GuruFocus.com

2 months ago

Exelixis Inc (EXEL) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ...

Morningstar Research

2 months ago

Analyst Report: Exelixis, Inc.

Exelixis (EXEL) Q3 2024 Earnings Call Transcript

Motley Fool

2 months ago

Exelixis (EXEL) Q3 2024 Earnings Call Transcript

Exelixis (EXEL) Reports Q3 Earnings: What Key Metrics Have to Say

Zacks

2 months ago

Exelixis (EXEL) Reports Q3 Earnings: What Key Metrics Have to Say

MT Newswires

2 months ago

Exelixis Q3 Non-GAAP Earnings, Revenue Rise; Updates Guidance

Exelixis (EXEL) Q3 Earnings and Revenues Beat Estimates

Zacks

2 months ago

Exelixis (EXEL) Q3 Earnings and Revenues Beat Estimates

Associated Press Finance

2 months ago

Exelixis: Q3 Earnings Snapshot

Exelixis Announces Third Quarter 2024 Financial Results and Provides Corporate Update

Business Wire

2 months ago

Exelixis Announces Third Quarter 2024 Financial Results and Provides Corporate Update

Zacks Industry Outlook Highlights Exelixis, Blueprint Medicines, CRISPR, Amicus and Verona Pharma

Zacks

2 months ago

Zacks Industry Outlook Highlights Exelixis, Blueprint Medicines, CRISPR, Amicus and Verona Pharma

Why Exelixis (EXEL) is a Top Momentum Stock for the Long-Term

Zacks

2 months ago

Why Exelixis (EXEL) is a Top Momentum Stock for the Long-Term

5 Biotech Stocks Likely to Outperform as Industry Prospects Look Bright

Zacks

2 months ago

5 Biotech Stocks Likely to Outperform as Industry Prospects Look Bright

Here's Why Exelixis (EXEL) is a Great Momentum Stock to Buy

Zacks

2 months ago

Here's Why Exelixis (EXEL) is a Great Momentum Stock to Buy

Intra-Cellular Therapies (ITCI) Expected to Beat Earnings Estimates: Should You Buy?

Zacks

2 months ago

Intra-Cellular Therapies (ITCI) Expected to Beat Earnings Estimates: Should You Buy?

1 No-Brainer Stock to Buy With $40

Motley Fool

2 months ago

1 No-Brainer Stock to Buy With $40

Exelixis (EXEL) Earnings Expected to Grow: Should You Buy?

Zacks

2 months ago

Exelixis (EXEL) Earnings Expected to Grow: Should You Buy?

Why Exelixis (EXEL) is a Top Value Stock for the Long-Term

Zacks

2 months ago

Why Exelixis (EXEL) is a Top Value Stock for the Long-Term

EXEL or CSLLY: Which Is the Better Value Stock Right Now?

Zacks

2 months ago

EXEL or CSLLY: Which Is the Better Value Stock Right Now?

Biotech Stock Roundup: VNDA, JAZZ Up on Updates, NVAX Suffers Setback & More

Zacks

2 months ago

Biotech Stock Roundup: VNDA, JAZZ Up on Updates, NVAX Suffers Setback & More

Exelixis (EXEL) Soars 8.6%: Is Further Upside Left in the Stock?

Zacks

2 months ago

Exelixis (EXEL) Soars 8.6%: Is Further Upside Left in the Stock?

Exelixis Gets Favorable Ruling in Patent Litigation With MSN

Zacks

2 months ago

Exelixis Gets Favorable Ruling in Patent Litigation With MSN

MT Newswires

2 months ago

Morgan Stanley Lifts Price Target on Exelixis to $30 From $28, Keeps Equalweight Rating

MT Newswires

2 months ago

RBC Raises Price Target on Exelixis to $34 From $30, Keeps Outperform Rating

Exelixis to Release Third Quarter 2024 Financial Results on Tuesday, October 29, 2024

Business Wire

2 months ago

Exelixis to Release Third Quarter 2024 Financial Results on Tuesday, October 29, 2024

Exelixis Announces Update on Second Patent Litigation Trial with MSN Laboratories

Business Wire

2 months ago

Exelixis Announces Update on Second Patent Litigation Trial with MSN Laboratories

Exelixis, MRK Collaborate for Combination Studies on HNSCC and RCC

Zacks

2 months ago

Exelixis, MRK Collaborate for Combination Studies on HNSCC and RCC

Exelixis and MSD to trial cancer therapies together in clinical collaboration

Clinical Trials Arena

2 months ago

Exelixis and MSD to trial cancer therapies together in clinical collaboration

MT Newswires

2 months ago

Exelixis, Merck Partner for Trials of Cancer Combination Therapies

Exelixis and Merck Sign Clinical Development Collaboration to Evaluate Investigational Zanzalintinib in Combination with KEYTRUDA® (pembrolizumab) in Head and Neck Cancer and in Combination with WELIREG® (belzutifan) in Renal Cell Carcinoma

Business Wire

2 months ago

Exelixis and Merck Sign Clinical Development Collaboration to Evaluate Investigational Zanzalintinib in Combination with KEYTRUDA® (pembrolizumab) in Head and Neck Cancer and in Combination with WELIREG® (belzutifan) in Renal Cell Carcinoma

MT Newswires

2 months ago

Morgan Stanley Lifts Price Target on Exelixis to $28 From $26, Keeps Equalweight Rating

ONCOLOGY COMMERCIALIZATION LEADER P.J. HALEY TO JOIN NETRAMARK BOARD OF DIRECTORS

CNW Group

2 months ago

ONCOLOGY COMMERCIALIZATION LEADER P.J. HALEY TO JOIN NETRAMARK BOARD OF DIRECTORS

Argus Research

2 months ago

EXEL: Rating increased to a BUY

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick

Zacks

2 months ago

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick

Exelixis Gains 20.7% in Three Months: Is This the Right Time to Buy?

Zacks

2 months ago

Exelixis Gains 20.7% in Three Months: Is This the Right Time to Buy?

MT Newswires

2 months ago

RBC Raises Price Target on Exelixis to $30 From $27, Keeps Outperform Rating

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

Zacks

3 months ago

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

EXEL vs. CSLLY: Which Stock Is the Better Value Option?

Zacks

3 months ago

EXEL vs. CSLLY: Which Stock Is the Better Value Option?

2 Growth Stocks to Buy With Less Than $100

Motley Fool

3 months ago

2 Growth Stocks to Buy With Less Than $100

MT Newswires

3 months ago

Exelixis Insider Sold Shares Worth $659,500, According to a Recent SEC Filing

Exelixis, Inc.'s (NASDAQ:EXEL) institutional investors lost 4.0% over the past week but have profited from longer-term gains

Simply Wall St.

3 months ago

Exelixis, Inc.'s (NASDAQ:EXEL) institutional investors lost 4.0% over the past week but have profited from longer-term gains

Here's Why Exelixis (EXEL) is a Strong Momentum Stock

Zacks

3 months ago

Here's Why Exelixis (EXEL) is a Strong Momentum Stock

MT Newswires

3 months ago

Exelixis Faces 'Modest Growth' Prospects, Patent Risk With Limited Near-Term Upside, UBS Says

MT Newswires

3 months ago

UBS Initiates Exelixis at Neutral

Here's Why Exelixis (EXEL) is a Strong Value Stock

Zacks

3 months ago

Here's Why Exelixis (EXEL) is a Strong Value Stock

Ipsen shelves Cabometyx combo in prostate cancer after Phase III miss

Pharmaceutical Technology

3 months ago

Ipsen shelves Cabometyx combo in prostate cancer after Phase III miss

Exelixis Announces Final Results from Phase 3 Pivotal CABINET Study Evaluating Cabozantinib in Advanced Neuroendocrine Tumors Presented at ESMO 2024 and Published in New England Journal of Medicine

Business Wire

3 months ago

Exelixis Announces Final Results from Phase 3 Pivotal CABINET Study Evaluating Cabozantinib in Advanced Neuroendocrine Tumors Presented at ESMO 2024 and Published in New England Journal of Medicine

Exelixis Presents Final Overall Survival Results from Phase 3 CONTACT-02 Pivotal Study Evaluating Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Metastatic Castration-Resistant Prostate Cancer at ESMO 2024

Business Wire

3 months ago

Exelixis Presents Final Overall Survival Results from Phase 3 CONTACT-02 Pivotal Study Evaluating Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Metastatic Castration-Resistant Prostate Cancer at ESMO 2024

Exelixis, Inc. (EXEL): Among Hedge Funds’ Top Biotech Stock Picks

Insider Monkey

3 months ago

Exelixis, Inc. (EXEL): Among Hedge Funds’ Top Biotech Stock Picks

Exelixis (EXEL) Down 3.4% Since Last Earnings Report: Can It Rebound?

Zacks

3 months ago

Exelixis (EXEL) Down 3.4% Since Last Earnings Report: Can It Rebound?

Why Exelixis (EXEL) is a Top Momentum Stock for the Long-Term

Zacks

4 months ago

Why Exelixis (EXEL) is a Top Momentum Stock for the Long-Term

Share on Social Networks: